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Abstract
Background: Currently, there is one Behçet’s disease (BD) specific self reporting questionnaire developed and
published in the literature, The Leeds BD-quality of life (QoL). We conducted a cross-cultural adaptation and
validation of the Arabic version of the Leeds BD-QoL
Methods: A cross-sectional study was conducted among 41 consecutive patients attending rheumatology clinics
at the American University of Beirut Medical Center between June and December 2007. The BD-QoL questionnaire,
the Katz Index of Activities of Daily Living (ADL) and the Lawton Instrumental Activities of Daily Living (IADL)
questionnaires were co-administered during the same visit, and severity scores were calculated. Cross-cultural
adaptation of BD-QoL was performed using forward and backward translations of the original questionnaire.
Internal consistency and test-retest reliability of the final version were determined. Exploratory Factor Analysis (EFA)
was used to assess the dimensionality of the scale items. External construct validity was examined by correlating
Arabic BD-QoL with the severity score, ADL and IADL.
Results: The 30 items of the adapted Arabic BD-QoL showed a high internal consistency (KR-20 coefficient 0.89)
and test-retest reliability (Spearman’s test 0.91). The convergence of all 30 items suggests that the 30-item adapted
Arabic BD-QoL scale is unidimensional. BD-QoL did not correlate with any of the patients’ demographics. Still, it
was positively correlated with patient severity score (r 0.4, p 0.02), and IADL (but not ADL).
Conclusions: This cross-cultural adaptation has produced an Arabic BD-QoL questionnaire that is now available for
use in clinical settings and in research studies, among Arabic speaking patients.
Keywords: Beh?ç?et?’?s disease Quality of life, Arabic version of BD-QoL, Cross-cultural adaptation, Validity and
reliability
Background
Behçet’s disease (BD) is a multisystem inflammatory dis-
order of unclear etiology characterized by recurrent oral
and genital ulcers, skin lesions and uveitis. Other mani-
festations include arthritis, a positive pathergy test,
thrombophlebitis, central nervous system disease and
gastrointestinal ulcerations [1-4]. Patients with BD suffer
a variety of activity limitations (disability) and restriction
of participation in many areas of life (handicap) [5].
Health related quality of life HRQoL has become an
important outcome measure in the assessment of
chronic disabling conditions, including BD [5,6]. While
disease generic questionnaires as the Medical Outcomes
Study Short-Form (SF-36) and others are used for
patients with musculoskeletal diseases, it has been advo-
cated that disease-specific HRQoL questionnaires are
better suited than generic instruments for rheumatic
diseases, as they might be more responsive to clinical
change, and are appropriate to evaluate specific thera-
peutic interventions [7-12]. Currently, there is one BD-
specific self reporting questionnaire developed and pub-
lished in the literature, the Leeds BD-QoL available in
the English and Korean languages [13].
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any medium, provided the original work is properly cited.The aim of the present study is to conduct a cross-
cultural adaptation and validation of an Arabic version
of the BD-QoL and produce a reliable and valid Arabic
version of the instrument.
Methods
Patient Recruitment and Assessment
Forty one patients satisfying the International Study
Group (ISG) criteria for diagnosis of BD and attending
the rheumatology clinics at the American University of
Beirut-Medical Center (AUB-MC) between June and
December 2007 were enrolled [14]. Patients enrolled in
this study did not have psychiatric illness or psychiatric
treatments that would affect their ability to complete
the questionnaire. The Leeds BD-QoL, the Katz Index
of Activities of Daily Living (ADL) and the Lawton
Instrumental Activities of Daily Living (IADL) question-
naires were self-administered to the patients on the day
of the visit day [5,15,16]. A complete history and physi-
cal exam were also performed at the visit. Symptoms at
the time of the study visit were recorded and those suf-
fered over the course of the disease were derived from
the Behçet’s Disease Database at AUB-MC [17]. The
study was approved by the Institutional Review Board
and informed consent was obtained from all patients.
Clinical Severity Score
Severity score was calculated as the sum of 1 point for
each mild symptom (oral aphthosis, genital ulcers,
arthralgia and typical skin lesions such as erythema
nodosum, papulopustular lesions and folliculitis), 2
points for each moderate symptom (arthritis, deep vein
thrombosis of the legs, anterior uveitis and gastrointest-
inal involvement) and 3 points for each severe symptom
(posterior/panuveitis, retinal vasculitis, arterial thrombo-
sis, neuro-Behçet’s and bowel perforation). Patients were
categorized into three groups according to their score:
severe (≥7), moderate (4- 6) and mild group (<4) [18].
Outcome Measures Used to Assess Quality of Life
Leeds BD-QoL is a composed of 30 items, answered
true (1) or false (0), yielding a score ranging from 0 to
30 [5]. Prior to the study, the developers of the Leeds
BD-QoL were contacted and the permission to use the
scale was granted.
Katz ADL: the Katz Index of Activities of Daily Living
(ADL) scale is a 6-item tool used to assess functional
dependency status of individuals [15]. ADL disability
was defined as needing help with one or more of the
activities.
Lawton IADL: the Lawton Instrumental Activities of
Daily Living (IADL) scale captures a different dimension
of disability than Katz ADL scale. IADL disability was
defined as having difficulty in one or more of activities
[16].
Cross-Cultural Adaptation
Guillemin and colleagues suggest five different examples
of cross-cultural adaptation; the last scenario is the
application of the questionnaire in a different culture,
language and country [19]. Cross-cultural adaptation
aims to reach the equivalence between the original
source (in the UK) and target version (in Lebanon) of
the questionnaire. More importantly all items must be
adapted culturally to maintain the content validity of the
scale at a conceptual level across different cultures
[20,21]. We followed the five steps described by Guille-
min and colleagues and Beaton and colleagues, intended
for a questionnaire of self-report-health status measures,
as follows [19,20].
Stage I: initial translation; a bilingual translator whose
mother tongue is Arabic generated an independent
translation in Arabic, referred to as T1. The translator
produced a written report of the completed translation.
The translator was not aware of the concept being
quantified and had no medical or clinical background
about BD.
Stage II: synthesis of the translation; three authors (Z.
T., A.S., T.A.) synthesized the results of the translation
and agreed on a common modified Arabic version,
referred to as T2. Their comments were mostly con-
cerning the wording of the Arabic questionnaire and
whenever appropriate modifications were made.
Stage III: back translation (BT); two English transla-
tors, working from the T2 version, translated back the
Arabic version of the BD-QoL into English. Both trans-
lators were totally blind to the original version, unaware
of the concepts explored, and had no medical back-
ground. The first translator was a certified translator
and the second was an MSc student, both native speak-
ers of Arabic and proficient in English. Translators pro-
duced a written report of the back translations (BT1
and BT2) that they completed. Three authors (Z.T., A.
S., and T.A.) synthesized one English version (BT12).
BT12 was then cross-examined with the original English
version and discrepancies corrected. This version was
later tested on 5 healthy individuals who were native
speakers of Arabic and fluent in English, reviewing
BT12 version and providing critical feedback on the
vocabulary. This was to ensure different aspects of
cross-cultural validity.
Stage IV: expert committee; a committee was set up
with the aim to cross-examine all versions against the
original BD-QoL questionnaire and produce the “pref-
inal version” of the Arabic BD-QoL. This Committee
was compromised of two rheumatologists, experts in BD
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a clinical research nurse coordinator (H.P.). Each item
was discussed and evaluated from all the viewpoints of
the different professionals in the committee. Their com-
ments were mostly concerning the wording of the ques-
tionnaire and where appropriate, changes were made in
accordance with the suggestions. This resulted in a pre-
final version of the Arabic questionnaire that was tested
on 3 healthy individuals and 3 patients with medical ill-
nesses other than BD. All 6 participants completed the
questionnaire within 5 minutes, and reported that all
items, except for one - item 21, were simple and easy to
understand.
Stage V: test of the pre-final version; 5 patients with
BD and 6 patients with rheumatoid arthritis completed
the Arabic pre-final version of the BD-QoL question-
naire. The objective of this stage is to ensure that the
adapted version retains the adequacy of content, clarity
of wording and usefulness. All patients completed the
questionnaire and highlighted that the Arabic BD-QoL
was easy to understand and BD patients confirmed its
adequacy in addressing the QoL related to their disease.
The final version of the Arabic BD-QoL was then ready
for further statistical evaluation of its psychometric
properties, its reliability and validity (Table 1).
Analysis
Descriptive statistics were used to characterize the
patients’ socio-demographic and clinical manifestations,
severity scores and BD-QoL. All analyses were underta-
ken using Stata 10.0. A two-sample independent t-test
was conducted to compare means across binary
variables (e.g., BD-QoL scores by age), and one-way
ANOVA was used to compare means across categorical
variables.
Test-retest reliability was determined among 10 patients at
1 week intervals
The Spearman’s test was applied to determine the corre-
lation coefficient. A correlation coefficient of at least 0.7
is considered acceptable and anything over 0.8 is consid-
ered to be high [22,23].
Internal consistency was assessed using Kuder-
Richardson-20 (KR-20) coefficient of the set of 30
dichotomous items [23,24]. For research and group level
comparisons, KR-20 of 0.80 or higher is considered
acceptable and KR-20 > 0.9-0.95 may represent “redun-
dancy” in the scale and, thus allow further item reduc-
tion [22-24].
Construct validity
Exploratory Factor Analysis (EFA) was used to assess the
dimensionality of the items in the scale, or its factor struc-
ture. Prior to running the EFA, the relative frequency dis-
tributions of all 30 items were carefully explored. The
assessment scale was binary (true, not true), and thus the
correlations computed by the statistical software were tet-
rachoric correlations. Principal Components Analysis
(PCA) was used as the extraction method. To empirically
examine the number of factors, a number of measures
were examined: eigenvalues, a scree plot, and item factor
loadings. An eigenvalue greater than one is typically used
to reflect the number of underlying factors; however, this
criterion alone does not suffice as it tends to overestimate
the number of factors to be extracted. The scree plot is a
visual depiction of the eigenvalues; the number of data
points above the “elbow” indicates the appropriate number
of factors to be extracted [25].
The external nomological construct validity was exam-
ined by correlating the score of the Arabic version of
BD-QoL with the severity scores (using Pearson’s corre-
lation and linear regression), as well as ADL and IADL
(using two-sample independent t-test). We further stu-
died the correlation between BD-QoL and the patients’
demographics. Using a linear regression model, and
while controlling for IADL and ADL, we examined the
ability of BD severity (as determined by severity index)
to predict BD-QoL.
Results
Patients’ Demographics
The total sample (n = 41) included 24 males and 17
females. The mean age at the time of the study was 34
± 11 years. The characteristics of the patient in repre-
sented in table 2. All patients were Lebanese whose
mother tongue is Arabic. Patients displayed a spectrum
of clinical manifestations during the progression of their
disease, and at the time of the study visit.
Table 1 Percent responses to BD-QoL as recorded by the
41 patients
Questions n % Questions n %
Q1 12 29 Q16 17 41
Q2 7 17 Q17 19 46
Q3 14 34 Q18 12 29
Q4 13 31 Q19 16 39
Q5 11 27 Q20 16 39
Q6 22 54 Q21 19 46
Q7 12 29 Q22 14 34
Q8 10 24 Q23 5 12
Q9 6 15 Q24 21 51
Q10 10 24 Q25 11 27
Q11 7 17 Q26 7 17
Q12 11 27 Q27 6 15
Q13 10 24 Q28 18 44
Q14 11 27 Q29 7 17
Q15 22 54 Q30 8 19
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The mean of the severity score was 9 ± 3.41 and was
statistically higher in males (10.08) compared to females
(7.47) (p-value: 0.01). The severity score was not related
to any other variable (age, educational level, living
arrangement, employment or marital status of the
patients).
BD-QoL
The mean BD-QoL was 9.12 (SD 6.69, and 95% CI 7.01-
11.12); the percent distribution of the responses to each
item are shown in table 2. The BD-QoL scores were
higher in males (10.04, SD 6.89) compared to females
(7.82, SD 6.38) but not statistically significant. The
mean of BD-QoL scores were significantly higher in the
group of patients older than 35 years (7.10, SD 4.91)
compared to those aged 18-35 years (11.47, SD 7.80) [p-
value: 0.03]. Despite being statistically significant, these
results should be interpreted with caution given the
width of CI. The way we grouped our patients could
have resulted in this statistically significant result. There
was a trend for higher BD-QoL scores in the group with
lower education but the finding was not statistically sig-
nificant (p = 0.11). The BD-QoL scores were not related
to the patients’ marital or employment status (Table 3)
Activities of Daily Living (ADL/IADL)
Around 27% of the patients had difficulty in at least one
ADL or IADL items and 27% patients had difficulty in
at least one IADL items (17% of the patients reporting
both).
Test-retest reliability and internal consistency of the final
Arabic version
The 30 items of the final adapted Arabic BD-QoL
showed a high internal consistency (KR-20 coefficient
0.89) and a high test-retest reliability (Spearman’st e s t ;
0.91, p < 0.01).
Table 2 Socio-demographic characteristics and clinical
manifestations of 41 patients with BD
Number of
patients
Percentage of
patients
Socio-demographics
Gender
Male 24 59
Female 17 41
Education
Illiterate 1 2.4
Read and Write 1 2.4
Primary 4 9.8
Intermediate 8 19.5
Secondary 7 17.1
Technical 5 12.2
University 15 36.6
Marital Status
Single 20 48.8
Married 20 48.8
Divorced 1 2.4
Employment
Unemployed 20 51.2
Employed 19 48.8
Clinical Manifestations
Oral ulcers 41 100.0
Genital Ulcer 30 73.2
Skin manifestations 41 100.0
Eye Disease 29 70.7
Blindness 2 4.9
Vascular involvement 14 34.1
Neurologic
involvement
27 65.9
Athralgia/arthritis 29 70.7
Epidedimitis 3 7.3
Table 3 Comparing BD-QoL scores by demographics for
41 patients
Mean SD 95% CI p
value
Sex
Male (n = 24) 10.04 6.89 7.13, 12.95 0.30
Female (n = 17) 7.82 6.83 4.54, 11.10
Age
18-35 years (n = 22) 7.10 4.91 4.92, 9.26 0.03
>35 years (n = 19) 11.47 7.80 7.72, 15.23
Marital status
Single (n = 20) 9.45 5.62 6.81, 12.08 0.76
Ever married (n = 21) 8.81 7.71 5.30, 2.32
Education*
Low (n = 6) 12.33 10.00 4.32, 20.34 0.11
Intermediate (n = 20) 10.05 6.50 7.23, 12.87
High (n = 15) 6.6 4.81 4.17, 9.03
Employment
Student (n = 6) 4.33 2.94 1.98, 6.68 0.15
Home maker (n = 7) 8.14 8.10 2.15, 14.13
Part time (n = 4) 11.75 9.11 2.84, 20.66
Full time (n = 18) 9.10 5.42 6.57, 15.62
Disabled (n = 5) 14.2 8.76 6.52, 7.68
Number of household
members**
0-5 (n = 22) 7.95 5.34 5.59, 10.32 0.23
6-9 (n = 19) 10.47 7.92 6.66, 14.30
* Low (illiterate, read and write, and primary), Intermediate (intermediate,
secondary, and technical), and high (university)
** Number of household members dichotomized as mean or below, and
above mean
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Content Validity
In stage IV of the cross-cultural adaptation, the con-
struction of the sentences in the translated version of
BD-QoL proved to be the major source of debate
among the committee members. In some cases items
were rephrased to make them comprehensible, still
maintaining the original meaning. We kept the language
in the Arabic version informal and simple, following the
English version, although in some cases the wording
was slightly modified to better suit the Arabic style.
Few expressions proved problematic: in particular Q5,
Q7, Q9, Q10, Q15, and Q21, for the forward translators,
consequently causing the back translation to be discor-
dant with the original version. The Committee agreed
on the following modifications of the final Arabic ver-
sion. For Q5 we added “regular things” in the Arabic
version referring to “daily activities”,a n df o rQ 7w e
added “daily life” to the Arabic version instead of “life”.
Q9 was simplified in the Arabic version although keep-
ing the original meaning of the English version, for Q10
“stressful” was substituted by “disturbed” in the Arabic
version, and for Q15 “rely” was substituted by “trust” in
the Arabic version. Q21 was unclear for patients and we
added to the sentence (because of mouth ulceration) in
the Arabic version. In stage V patients confirmed that
the Arabic version of BD-QoL was easy to understand
and useful. A final versiono ft h eA r a b i cB D - Q o Lw a s
generated and is available upon request.
Internal Construct Validity: Convergence of items
Upon examining the PCA results of EFA, 10 compo-
nents had a value greater than 1; the first component
however had an eigenvalue of 8.77 followed by 2.38 for
t h es e c o n d ,2 . 0 9f o rt h et h i r d ,1 . 9 0f o rt h ef o u r t h ,w i t h
the remaining 6 components ranging from 1.07-1.68.
The first component accounted for 29% of the variance,
followed by 4-8% for each of the remaining 9 compo-
nents. While the eigenvalues suggest the extraction of
10 factors, the eigenvalue rule more often than not leads
to an overestimation of the number of underlying latent
factors.
The scree plot, suggested that a 1-factor solution is
optimal (Figure 1); in other words, the 30-item scale is
unidimensional. The ratio of the first to second eigenva-
lue in our sample was almost four (3.7), which is further
evidence for unidimensionality of the scale.
Upon examining all measures for extracting factors,
the results suggest that the 30-item scale is unidimen-
sional which means that the scale is measuring the same
thing (attribute) (Figure 1). The unidimensionality of the
adapted Arabic BD- QoL version is further evidence to
the convergence of all 30 items and is an indication of
its construct validity [25].
External Nomological Validity
BD-QoL did not correlate with any of the patients’
demographics. There was a statistically significant posi-
tively moderate correlation between the severity score
and BD-QoL (r 0.4, p-value 0.02). A one-unit increase
in the severity score was shown to predict a 0.7 unit
increase in the BD-QoL total score (b =0 . 7 1 ,p-value =
0.02, 95% CI 0.11-1.30).
BD-QoL was also independently related to IADL (but
not ADL) whereby the mean BD-QoL severity scores
were statistically significantly higher in those with any
IADL (10.81, 95% CI 8.39-13.23 vs. 8.33, 95% CI 7.16-
9.50 (p-value: 0.03). This could be potentially explained
by the fact that several of the IADL questions overlap
with BD-QoL items, in contrast to ADL, which is used
to assess the functional status of physically dependent
individuals.
Severity of BD was predicted by BD-QoL controlling
for the presence of any IADL (b: 0.71, 95% CI 0.10-1.30
p-value = 0.02), but not while controlling for any ADL
item (b: 0.53, 95% CI -0.08-1.14, p-value = 0.08).
Discussions
The evidence supporting the benefits of using a disease-
specific questionnaire to assess quality of life in rheuma-
tology including BD in English-speaking countries call
for an extension of their availability to other linguistic
groups. This becomes particularly important since dis-
ease-specific quality of life measures may evaluate the
impact of the disease on areas that are not adequately
addressed in routine clinical practice or in generic ques-
tionnaires that may lack one or more domains pertinent
to BD patients (e.g., problems with talking and eating
for patients with mouth ulceration, effect on
relationships).
The present paper described the cross-cultural adapta-
tion and validation of the Arabic version BD-QoL. The
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Figure 1 Screeplot of 30-item adapted Arabic BD-QoL.
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crucial in reaching an appropriate version, examining
the work from different points of view. The BD-QoL
was translated from English into Arabic using a rigorous
methodology; words were replaced, as necessary, to ren-
der BD-QoL items more valid in the Arabic language
within our cultural context [20]. Feedback expressed by
the patients on each item of the questionnaire in stage
V of the process provided an indispensable perspective
that ensured the simplicity and comprehensibility of the
Arabic version. For most patients, it took less than 10
minutes to complete the questionnaire. Furthermore,
the Arabic version of the BD-QoL was shown to be uni-
dimensional, highly reliable and of adequate construct
validity.
Patients in this study presented a relatively high
severity score of their disease. The major impact of the
disease was found in items 6, 15 and 24 that addressed
the patient’s ability to stand for long, his perception
about the future of his life and disease, and his own
worries about holding others back, respectively. This
also illustrates how BD affects several domains of a
patient’s life. Less impact was observed for items 9, 23
and 27, which assess the patient’s looks, their feeling
of uselessness due to the disease and their contact
with people, respectively. This could be related to the
ability of the patient to accept, cope and live with the
disease. In our study we showed a moderate correla-
tion between the BD-QoL and the severity score.
Indeed, we expected this result especially that previous
studies in BD and other rheumatic diseases have
shown that HRQoL do not always correlate strongly
(>0.7) with disease severity. Furthermore, HRQoL
assessment is considered as an independent outcome
measure in the assessment of rheumatic diseases. The
‘Outcome Measures in Rheumatology’ (OMERACT)
IV, recommended for both randomized clinical trials
and longitudinal observational studies, including
HRQoL as an outcome measure among others [6].
Similar to our results, a study on HRQoL in 41 BD
patients showed a low to moderate correlation with
disease activity [26]. More recently, Ertam et al.,
showed that HRQoL in 195 BD patients is impaired
and related with disease severity in BD [10].
The mean of BD-QoL scores were higher in males
compared to female but not statistically different;
whether the higher severity scores contributed to
higher BD-QoL scores needs to be addressed in future
studies. BD disease activity is usually more severe
among younger patients and one would expect a lower
HRQoL in this group. However, in our study the older
group (age > 35 years) as compared to the younger
group (age < 35 years) had lower HRQoL with a higher
score on the BD-QoL questionnaire. Probably a longer
disease duration is a factor implicated in the worsening
of HRQoL with the potential damage accrue that
might occur with BD. All these research questions
need to be evaluated and addressed in multi-center
studies with patients of different ethnicities and larger
sample size.
Upon comparing our results with the reference
values from a Korean study that administered the BD-
QoL questionnaire consecutively to 201 patients, BD-
QoL scores in Koreans were lower. Moreover, BD-QoL
scores in their sample (predominantly female, 61%)
were statistically higher in females, a finding that was
possibly attributed to the higher rate of depression in
women.
Despite its offsetting strengths, the present study and
its findings need to be interpreted in light of a few lim-
itations. First, the sample size was small, particularly for
the exploratory factor analysis (EFA). Several different
recommendations have been made for the optimum
sample size for an EFA pertaining to either the absolute
sample size or the subject-to-variable ratios. Our sample
of 41 patients falls below the recommended levels, yet
was sufficient enough to exhibit sufficient power and
detect expected and statistically significant associations
between BD-QoL and other measures. Moreover, the
high internal consistency of the 30 items speaks to the
unidimensionality of the scale (as evidenced by the
EFA).
Conclusions
In summary, there is evidence that BD-QoL is accepted
b yB Dp a t i e n t sa n di tc o r r e l a t e dw i t ht h es e v e r i t ys c o r e
of the disease. An Arabic version Behçet’s disease qual-
ity of life is now available for testing and use in clinical
settings and research studies that assess the quality of
life in Arabic speaking patients. The majority of the BD
patients are from the areas surrounding the old Silk
Road in the Middle East and in Central Asia. We believe
that the use of the Arabic version of BD-QoL question-
naire together with the English, Korean and other
potential versions of BD-QoL would allow comparison
of cross-national findings.
What is already known on this subject?
Currently, there is one BD-specific self reporting ques-
tionnaire developed and published in the literature, the
Leeds BD-QoL along with its Korean version.
What does this study add?
Behçet’s Disease is more common in the Middle East
and Asia. This cross-cultural adaptation and validation
has produced an Arabic BD-QoL questionnaire that can
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Page 6 of 7be used in clinical and in research studies in these geo-
graphic areas. The Arabic version of the Leeds BD-QoL
questionnaire is reliable and valid.
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